Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
49.02
-0.72 (-1.45%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
December 22, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
December 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
December 15, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
December 15, 2023
From
Bristol Myers Squibb
Via
Business Wire
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
December 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
December 10, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
December 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
December 07, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
December 07, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Announces Dividend Increase
December 06, 2023
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
December 05, 2023
From
Bristol Myers Squibb
Via
Business Wire
3 stocking stuffers you can buy for yourself
November 29, 2023
These low-beta, deep-value high-yielding stocks are perfect stocking stuffers, even if you buy them for yourself. Rebound is expected in 2024.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
J&J, Gilead, BMS: A look at undervalued dividend payers
November 29, 2023
J&J, Gilead and Bristol Myers are among healthcare stocks with defensive qualities amid market volatility and a potential economic slowdown
Via
MarketBeat
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
November 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
2 overlooked stocks that crushed earnings but traded lower
November 20, 2023
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results
Via
MarketBeat
Exposures
Product Safety
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
November 15, 2023
From
Bristol Myers Squibb
Via
Business Wire
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
November 14, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END
Via
FinancialNewsMedia
High-yield, low-beta value plays for buy-and-hold investors
November 14, 2023
High-yield stocks that trade at a value and come with a lower-than-average beta can help mitigate portfolio volatility and boost returns over time.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference
November 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
November 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
November 09, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
November 06, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology
November 02, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
November 02, 2023
From
Bristol Myers Squibb
Via
Business Wire
Investor patience tested as pharmaceutical stocks take a tumble
November 01, 2023
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector
Via
MarketBeat
Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024
October 31, 2023
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
October 30, 2023
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.